Dr. Stewart Goldman, MD
Claim this profileLurie Children's Hospital-Chicago
Studies Brain Tumor
Studies Diffuse Intrinsic Pontine Glioma
13 reported clinical trials
26 drugs studied
Area of expertise
1Brain Tumor
H3.3K27M positive
IDH positive
H3F3A
2Diffuse Intrinsic Pontine Glioma
H3.3K27M positive
H3F3A
HLA-A positive
Affiliated Hospitals
Clinical Trials Stewart Goldman, MD is currently running
Dabrafenib + Trametinib + Hydroxychloroquine
for Brain Tumor
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Recruiting1 award Phase 1 & 216 criteria
Poly-ICLC
for Low-Grade Glioma
This trial is testing a medication called Poly-ICLC that boosts the immune system in children with NF1 who have brain tumors that don't respond to usual treatments. The goal is to see if this medication can help shrink or control the tumors by enhancing the body's natural defenses.
Recruiting1 award Phase 235 criteria
More about Stewart Goldman, MD
Clinical Trial Related8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Stewart Goldman, MD has experience with
- BGB-290
- Temozolomide
- K27M Peptide
- Nivolumab
- Optune System
- CX-4945
Breakdown of trials Stewart Goldman, MD has run
Brain Tumor
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Low Grade Glioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stewart Goldman, MD specialize in?
Stewart Goldman, MD focuses on Brain Tumor and Diffuse Intrinsic Pontine Glioma. In particular, much of their work with Brain Tumor has involved H3.3K27M positive patients, or patients who are IDH positive.
Is Stewart Goldman, MD currently recruiting for clinical trials?
Yes, Stewart Goldman, MD is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Stewart Goldman, MD has studied deeply?
Yes, Stewart Goldman, MD has studied treatments such as BGB-290, Temozolomide, K27M peptide.
What is the best way to schedule an appointment with Stewart Goldman, MD?
Apply for one of the trials that Stewart Goldman, MD is conducting.
What is the office address of Stewart Goldman, MD?
The office of Stewart Goldman, MD is located at: Lurie Children's Hospital-Chicago, Chicago, Illinois 60611 United States. This is the address for their practice at the Lurie Children's Hospital-Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.